A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

被引:7
|
作者
Xie, Peiling [1 ]
An, Rui [2 ]
Yu, Shibo [1 ]
He, Jianjun [1 ]
Zhang, Huimin [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Breast Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Hepatol Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; ER+/PR-/HER2-; Immune classification; Multi-omics; PROGESTERONE-RECEPTOR EXPRESSION; PREDICTIVE-VALUE; PD-1; BLOCKADE; CROSS-TALK; ESTROGEN; TAMOXIFEN; GROWTH; TUMORS; IMMUNOTHERAPY; MECHANISMS;
D O I
10.1186/s12967-021-03076-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The diversity and plasticity behind ER+/PR-/HER2- breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. Methods: Based on the immune-related gene expression profiles of 411 ER+/PR-/HER2- breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. Results: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-gamma response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. Conclusion: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, also provided important implications for clinical translations.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer
    Ramakrishna, M.
    Martin, S.
    Campbell, P. J.
    Futreal, P. A.
    Stratton, M. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S132 - S132
  • [22] Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
    Bischoff, Herve
    Espie, Marc
    Petit, Thierry
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, : 1210 - 1224
  • [23] Identification of key differentially expressed genes between ER-positive/HER2-negative breast cancer and ER-negative/HER2-negative breast cancer using integrated bioinformatics analysis
    Gan, Siyuan
    Dai, Haixia
    Li, Rujia
    Liu, Wang
    Ye, Ruifang
    Ha, Yanping
    Di, Xiaoqing
    Hu, Wenhua
    Zhang, Zhi
    Sun, Yanqin
    GLAND SURGERY, 2020, 9 (03) : 661 - 675
  • [24] The immunohistochemically “ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative” subgroup is not a surrogate for the normal-like subtype in breast cancer
    Ke-Da Yu
    Zhen-Zhou Shen
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2009, 118 : 661 - 663
  • [25] The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative'' subgroup is not a surrogate for the normal-like subtype in breast cancer
    Yu, Ke-Da
    Shen, Zhen-Zhou
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (03) : 661 - 663
  • [26] Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
    Richard Buus
    Belinda Yeo
    Adam R. Brentnall
    Marie Klintman
    Maggie Chon U. Cheang
    Komel Khabra
    Ivana Sestak
    Qiong Gao
    Jack Cuzick
    Mitch Dowsett
    Breast Cancer Research, 20
  • [27] Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
    Buus, Richard
    Yeo, Belinda
    Brentnall, Adam R.
    Klintman, Marie
    Cheang, Maggie Chon U.
    Khabra, Komel
    Sestak, Ivana
    Gao, Qiong
    Cuzick, Jack
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2018, 20
  • [28] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [30] Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
    Lundgren, Christine
    Bendahl, Par-Ola
    Borg, Ake
    Ehinger, Anna
    Hegardt, Cecilia
    Larsson, Christer
    Loman, Niklas
    Malmberg, Martin
    Olofsson, Helena
    Saal, Lao H.
    Sjoblom, Tobias
    Lindman, Henrik
    Klintman, Marie
    Hakkinen, Jari
    Vallon-Christersson, Johan
    Ferno, Marten
    Ryden, Lisa
    Ekholm, Maria
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (02) : 459 - 467